LLY

1,016.08

+0.3%↑

JNJ

242.62

-1.09%↓

ABBV

225.02

+0.64%↑

NVS

163.06

-0.06%↓

MRK

121.45

+0.45%↑

LLY

1,016.08

+0.3%↑

JNJ

242.62

-1.09%↓

ABBV

225.02

+0.64%↑

NVS

163.06

-0.06%↓

MRK

121.45

+0.45%↑

LLY

1,016.08

+0.3%↑

JNJ

242.62

-1.09%↓

ABBV

225.02

+0.64%↑

NVS

163.06

-0.06%↓

MRK

121.45

+0.45%↑

LLY

1,016.08

+0.3%↑

JNJ

242.62

-1.09%↓

ABBV

225.02

+0.64%↑

NVS

163.06

-0.06%↓

MRK

121.45

+0.45%↑

LLY

1,016.08

+0.3%↑

JNJ

242.62

-1.09%↓

ABBV

225.02

+0.64%↑

NVS

163.06

-0.06%↓

MRK

121.45

+0.45%↑

Home・Aktien・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Open

1.28 2.4

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.25

Max

1.32

Schlüsselkennzahlen
By Trading Economics
Einkommen	17M -26M
Angestellte	171
EBITDA	19M -23M

Dividenden
By Dow Jones
Nächstes Ergebnis	26. Feb. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-34M 68M
Vorheriger Eröffnungskurs	-1.12
Vorheriger Schlusskurs	1.28

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

19. Feb. 2026, 23:47 UTC

Market Talk

Global Equities Roundup: Market Talk

19. Feb. 2026, 23:47 UTC

Market Talk

Nikkei May Decline Amid Caution Over Potential U.S. Strike on Iran -- Market Talk

19. Feb. 2026, 23:39 UTC

Akquisitionen, Fusionen, Übernahmen

Swiss Re Corporate Solutions to Buy QBE Insurance's Global Trade Credit and Surety Business >SREN.EB

19. Feb. 2026, 23:38 UTC

Ergebnisse

Samsung Fire & Marine Insurance 2025 Net KRW2.020T Vs. Net KRW2.077T >000810.SE

19. Feb. 2026, 23:38 UTC

Ergebnisse

Samsung Fire & Marine Insurance 2025 Oper Pft KRW2.659T Vs. Pft KRW2.650T >000810.SE

19. Feb. 2026, 23:38 UTC

Ergebnisse

Samsung Fire & Marine Insurance 2025 Rev KRW24.779T Vs. KRW22.657T >000810.SE

19. Feb. 2026, 23:37 UTC

Market Talk

Gold Edges Lower on Possible Position Adjustment -- Market Talk

19. Feb. 2026, 23:34 UTC

Ergebnisse

Samsung Fire & Marine Insurance 4Q Net Profit Missed FactSet-Compiled Consensus

19. Feb. 2026, 23:34 UTC

Ergebnisse

Samsung Fire & Marine Insurance 4Q Net KRW234.38B Vs. Net KRW207.88B >000810.SE

19. Feb. 2026, 23:33 UTC

Ergebnisse

Samsung Fire & Marine Insurance 4Q Oper Pft KRW391.26B Vs. Pft KRW252.81B >000810.SE

19. Feb. 2026, 23:33 UTC

Ergebnisse

Samsung Fire & Marine Insurance 4Q Rev KRW6.083T Vs. KRW6.297T >000810.SE

19. Feb. 2026, 22:13 UTC

Market Talk

Goodman's Lack of Earnings Upgrade 'Largely Timing Related' -- Market Talk

19. Feb. 2026, 22:08 UTC

Ergebnisse

Fairfax Financial 4Q Rev $8.11B >FFH.T

19. Feb. 2026, 22:07 UTC

Ergebnisse

Eldorado Gold 4Q EPS $1.19 >ELD.T

19. Feb. 2026, 22:06 UTC

Ergebnisse

Centerra Gold: 2026 Consolidated Gold Production Expected 250,000 to 280,000 Ounces, Copper Production Expected 50M to 60M Pounds >CG.T

19. Feb. 2026, 22:05 UTC

Ergebnisse

Eldorado Gold 4Q Adj EPS 63c >ELD.T

19. Feb. 2026, 22:05 UTC

Ergebnisse

Eldorado Gold 4Q Rev $577.2M >ELD.T

19. Feb. 2026, 22:04 UTC

Ergebnisse

Eldorado Gold 4Q Gold Sales 126,923 Ounces >ELD.T

19. Feb. 2026, 22:04 UTC

Ergebnisse

Eldorado Gold 4Q Gold Production 123,416 Ounces >ELD.T

19. Feb. 2026, 21:50 UTC

Market Talk

Ergebnisse

Tech, Media & Telecom Roundup: Market Talk

19. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

19. Feb. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

19. Feb. 2026, 21:43 UTC

Ergebnisse

St Barbara 1H Underlying Profit A$1.3 Million Vs A$48.1 Million Loss Year Earlier

19. Feb. 2026, 21:42 UTC

Akquisitionen, Fusionen, Übernahmen

Palo Alto Networks Announces Offer to Purchase Relating to CyberArk Software Ltd.'s 0.00% Convertible Senior Notes Due 2030

19. Feb. 2026, 21:42 UTC

Ergebnisse

St Barbara 1H Revenue A$128.8 Million, Up 32% On-Year

19. Feb. 2026, 21:41 UTC

Ergebnisse

Correct: St Barbara 1H Net Loss A$249,000

19. Feb. 2026, 21:40 UTC

Ergebnisse

St Barbara 1H Net Loss A$249 Million

19. Feb. 2026, 21:39 UTC

Ergebnisse

Perseus Mining Reaffirms FY26 Production, AISC Guidance

19. Feb. 2026, 21:37 UTC

Ergebnisse

These Stocks Are Today's Movers: Walmart, Occidental, Klarna, Wayfair, Deere, Omnicom, EPAM, and More -- Barrons.com

19. Feb. 2026, 21:37 UTC

Ergebnisse

Century Aluminum Expects 1Q Adj EBITDA $215 M to $235 M >CENX

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Rating-Konsens

By TipRanks

Sell

1 ratings

Buy

Halten

Sell

Basierend auf 1 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.